Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has 8 years of Short term Debt data on file, last reported at $10.2 million in Q2 2023.

• On a quarterly basis, Short term Debt rose 211.57% year-over-year to $10.2 million in Q2 2023; TTM through Jun 2023 was $10.2 million, a 211.57% increase from a year earlier, with the FY2022 full-year figure at $8.5 million, up 42.19% from the prior year.
• Short term Debt for Q2 2023 stood at $10.2 million, roughly flat from $10.2 million in the prior quarter.
• Over the last five years, Short term Debt for RNAC reached as high as $21.5 million in Q2 2019 and fell as low as $460000.0 in Q1 2021.
• Historically, Short term Debt has averaged $10.0 million across 5 years, with a median of $8.4 million in 2020.
• Across the five-year window, Short term Debt slumped 97.27% in 2021 and jumped 1368.1% in 2023, its largest moves.
• Year by year, Short term Debt stood at $18.9 million in 2019, then slumped by 55.65% to $8.4 million in 2020, then dropped by 28.9% to $6.0 million in 2021, then soared by 42.19% to $8.5 million in 2022, then climbed by 20.75% to $10.2 million in 2023.
• Per Business Quant data, the three most recent Short term Debt figures were $10.2 million in Q2 2023, $10.2 million in Q1 2023, and $8.5 million in Q4 2022.